Pharma News

ASP-3082 by Astellas Pharma for Metastatic Colorectal Cancer: Likelihood of Approval

ASP-3082 is under clinical development by Astellas Pharma and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASP-3082’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ASP-3082 overview

ASP-3082 is under development for the treatment of solid tumors and metastatic colorectal cancer. It is administered through intravenous route as infusion. The therapeutic candidate is a small molecule acts by targeting KRAS G12D.

Astellas Pharma overview

Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline possesses drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; Rheumatoid arthritis and non-dialysis patients; menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

For a complete picture of ASP-3082’s drug-specific PTSR and LoA scores, buy the report here.




Source link
#ASP3082 #Astellas #Pharma #Metastatic #Colorectal #Cancer #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *